Cambridge Experimental Cancer Medicine Centre (ECMC)

The Cambridge ECMC aims to develop molecular prognostic and diagnostic tests to aid treatment decisions. The Centre focuses on genetic predisposition to cancer and the identification of high risk groups. This is being achieved by building on local strengths in genomics, pharmacogenetics, molecular pathology, molecular imaging, clinical informatics and computational biology.

ECMC Network

Contacts

University of Cambridge
Cancer Research UK Cambridge Institute, Department of Oncology
University of Cambridge
Cancer Research UK Cambridge Institute
ECMC Centres

Experimental Cancer Medicine Centres (ECMC) researchers are world-leading scientists and clinicians who drive the discovery, development and testing of new treatments to combat cancer. The funding supports over 200 staff involved in early phase trials and translational research. The ECMC Network is made of up 18 Centres across the UK. There are adult and paediatric Centres. Find out more about the Centres.

Benefiting Patients

The Cambridge ECMC aims to develop molecular prognostic and diagnostic tests to aid treatment decisions. The Centre focuses on genetic predisposition to cancer and the identification of high risk groups. This is being achieved by building on local strengths in genomics, pharmacogenetics, molecular pathology, molecular imaging, clinical informatics and computational biology.

The overall aim of the Cambridge ECMC is to deliver personliased cancer medicine as the means to better achieve cancer control as the means to better achieve cancer control. This personalistion of cancer medicine used the detailed characterisations of both the neoplasm and of the patient afflicated by it to improve screening, diagnosis, trageted treatment, and treatment monitoring

Find out more about the Cambridge ECMC programme here.

Research Areas in Cambridge

Cancer control will be ultimately achieved through prevention, through early diagnosis, through better use of currently available treatments, and through the development of new better targeted therapeutics. The Cambridge ECMC provide support related to each of these areas. In particular, the Cambridge ECMC will provide infrastructure support for 6 broad research areas:

  • Early-phase clinical trials and experimental therapeutics
  • Novel cancer imaging Biomarkers (laboratory-based)
  • Tumour monitoring
  • Translational research in late-phase trials
  • Screening and intervention in high-risk groups